ClinicalTrials.gg
CompletedNCT03721978Updated Oct 17, 2024Results posted

REVEAL 2 Trial (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL)

A Phase 3 interventional study of VGX-3100 and Matched Placebo in Cervical Dysplasia, Cervical High Grade Squamous Intraepithelial Lesion and HSIL, sponsored by Inovio Pharmaceuticals. Completed at 53 sites in 10 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-17.

Sponsored by Inovio Pharmaceuticals · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
203
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 109 studies in Uterine Cervical Dysplasia with a site in United States — 10 open to participants now, 14 under way, none of them phase 3. Uterine Cervical Dysplasia · United States.

Enrollment
25th of 86
203 · median 80
Started
2019
with 1 other
Phase 3
12 of 109
none open now
Registered
88th of 109
by date
Lead sponsor
3 of 109
Inovio Pharmaceuticals

Among the 109 studies in Uterine Cervical Dysplasia with a site in United States, this one is the 25th largest by enrollment of the 86 interventional ones that give a count, is one of 2 that started in 2019, is one of 12 in phase 3, and was the 88th registered.

Uterine Cervical Dysplasia

409 studies on the registry are indexed under Uterine Cervical Dysplasia; 76 are open to participants now.

Browse Uterine Cervical Dysplasia studies →

Open to participants now

10 of the 109 studies in Uterine Cervical Dysplasia with a site in United States are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 43 Uterine Cervical Dysplasia studies recruiting now, 19 (44%) set no upper age limit and 21 (49%) stop at 75 or younger; 3 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 109 studies in Uterine Cervical Dysplasia with a site in United States, or all of them as a file.
02

Study summary

HPV-303 is a prospective, randomized, double-blind, placebo-controlled study of VGX-3100 delivered intramuscularly (IM) followed by electroporation (EP) delivered with CELLECTRA™ 5PSP in adult women with histologically confirmed high-grade squamous intraepithelial lesions (HSIL) (cervical intraepithelial neoplasia grade 2 [CIN2] or grade 3 [CIN3]) of the cervix, associated with human papillomavirus (HPV-16) and/or HPV-18.

03

Conditions studied

  • Cervical Dysplasia
  • Cervical High Grade Squamous Intraepithelial Lesion
  • HSIL

Keywords

  • Cervical intraepithelial neoplasia (CIN)
  • CIN 2
  • CIN 3
  • Human papillomavirus (HPV)
  • HPV-16
  • HPV-18
  • High Grade Squamous Intraepithelial Lesion (HSIL)
  • papillomavirus
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women aged 18 years and above
  • Confirmed cervical infection with HPV types 16 and/or 18 at screening
  • Cervical tissue specimen/slides provided to Study Pathology Adjudication Committee for diagnosis scheduled to be collected within 10 weeks prior to anticipated date of first dose of study drug
  • Confirmed histologic evidence of cervical HSIL at screening
  • Must be judged by Investigator to be an appropriate candidate for the protocol-specified procedure required at Week 36
  • With respect to their reproductive capacity must be or surgically sterile or willing to use a method with failure rate of less than 1% per year when used consistently and correctly from screening until Week 36
  • Normal screening (ECG)

Exclusion criteria

Exclusion Criteria:

  • Microscopic or gross evidence of adenocarcinoma-in-situ (AIS), high grade vulvar, vaginal, or anal intraepithelial neoplasia or invasive cancer in any histopathologic specimen at screening
  • Cervical lesion(s) that cannot be fully visualized on colposcopy
  • History of endocervical curettage (ECC) which showed cervical HSIL indeterminate, or insufficient for diagnosis
  • Treatment for cervical HSIL within 4 weeks prior to screening
  • Pregnant, breastfeeding or considering becoming pregnant during the study
  • History of previous therapeutic HPV vaccination
  • as a result of underlying illness or treatment
  • Receipt of any non-study, non- within 2 weeks of Day 0
  • Receipt of any non-study, live vaccine within 4 weeks of Day 0
  • Current or history of , medically unstable disease or condition which, in the judgment of the investigator, would jeopardize the safety of the participant, interfere with study assessments or endpoint evaluation, or otherwise impact the validity of the study results
  • Presence of acute or chronic bleeding or clotting disorder that would contraindicate IM injections, or use of blood thinners within 2 weeks of Day 0
  • Participation in an interventional study with an compound or device within 30 days of signing
  • Less than two acceptable sites available for IM injection
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
203 participants (actual)

Study arms

  • Experimental
    VGX-3100 + EP

    Participants received 3 IM injections of 6 mg (in 1 mL) VGX-3100 followed by EP using the CELLECTRA™-5PSP device on Day 0, Week 4, and Week 12.

    Biological: VGX-3100 · Device: CELLECTRA™-5PSP

  • Placebo comparator
    Matched Placebo + EP

    Participants received 3 IM injections of 1 mL VGX-3100 matching placebo followed by EP using the CELLECTRA™-5PSP device on Day 0, Week 4, and Week 12.

    Biological: Matched Placebo · Device: CELLECTRA™-5PSP

Interventions

  • BiologicalVGX-3100

    1 milliliter (mL) VGX-3100 injected IM.

  • BiologicalMatched Placebo

    1 mL of matched Placebo injected IM.

  • DeviceCELLECTRA™-5PSP

    CELLECTRA™-5PSP used for EP following IM injection of VGX 3100.

06

What researchers measure

Primary outcomes

  1. Baseline Biomarker-positive Participants for ITT Population: Percentage of Participants With No Histologic Evidence of Cervical HSIL on Histology Sample and No Evidence of HPV-16 and/or HPV-18 in Cervical Samples

    Baseline biomarker-positive participants with no histologic (i.e., biopsies or excisional treatment) evidence of cervical HSIL, no evidence of HPV-16 and/or HPV-18 at Week 36, and participants who did not have unscheduled excision or biopsy sample obtained between the initial dose up to Week 36 were considered to be responders. No evidence of HSIL was defined by histology as negative, squamous atypia, or low-grade intraepithelial lesion (LSIL). Cervical samples for HPV-16 and/or HPV-18 were collected using the ThinPrep™. The efficacy time frame is defined by a biopsy or surgical excision at any time starting from 14 days prior to the protocol-specified target date of Week 36. The first tissue removal sample within the time frame determines the histology endpoint.

    Time frame: At Week 36

Secondary outcomes

  1. Baseline Biomarker-positive Participants for Safety Population: Number of Participants With Any Local and Systemic Adverse Events (AEs)

    An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of the pharmaceutical product, whether or not considered related to the pharmaceutical product. Pre-existing conditions which worsen during a study are also considered as AEs. Nausea, fatigue, injection site bruising, injection site erythema, injection site haematoma, injection site induration, injection site pain, injection site pruritus, injection site swelling, malaise, pyrexia, arthralgia, myalgia, headache and erythema were considered as local and systemic AEs for baseline biomarker-positive participants for safety population.

    Time frame: From Baseline to Week 40

  2. Safety Population: Number of Participants With Local and Systemic AEs

    An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of the pharmaceutical product, whether or not considered related to the pharmaceutical product. Pre-existing conditions which worsen during a study are also considered as AEs. Nausea, chills, fatigue, injection site bruising, injection site erythema, injection site haematoma, injection site haemorrhage, injection site induration, injection site oedema, injection site pain, injection site paraesthesia, injection site pruritus, injection site swelling, malaise, pain, pyrexia, temperature regulation disorder, arthralgia, myalgia, headache and erythema were considered as local and systemic AEs for safety population.

    Time frame: From Baseline to Week 40

  3. Baseline Biomarker-positive Participants for Safety Population: Number of Participants With Any Treatment Emergent AEs (TEAEs) and Serious TEAEs (Including Suspected Unexpected Serious Adverse Reaction [SUSAR] and Unexpected Adverse Device Effect [UADE])

    AE is any untoward medical occurrence in a participant administered a pharmaceutical product, which does not necessarily have a causal relationship with the treatment. Serious AE (SAE) is any experience that suggested significant hazard, contraindication, side effect/precaution, \& fulfilled any of the following: fatal, life-threatening, required in-patient hospitalization/prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was medically significant/required intervention to prevent other outcomes. TEAEs are any AEs starting on or after the first administration of any investigational product (IP). TEAEs included both serious and non-serious TEAEs. UADE is any SAE on health/safety or any life-threatening problem/death caused by, or associated with a device, if that effect, problem/death was not previously identified in nature, severity/degree of incidence in the investigational plan or application.

    Time frame: From Baseline to Week 40

  4. Safety Population: Number of Participants With Any TEAEs and Serious TEAEs (Including SUSAR and UADE)

    AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have a causal relationship with the treatment. SAE is any experience that suggested significant hazard, contraindication, side effect, or precaution, and fulfilled any of the following criteria: fatal, life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was medically significant or required intervention to prevent other outcomes. TEAEs are defined as AEs starting on or after the first administration of any IP. TEAEs included both serious and non-serious TEAEs. UADE is any SAE on health/safety or any life-threatening problem/death caused by, or associated with a device, if that effect, problem/death was not previously identified in nature, severity/degree of incidence in the investigational plan or application.

    Time frame: From Baseline to Week 40

  5. ITT Population: Percentage of Participants With No Histologic Evidence of Cervical HSIL on Histology Sample and No Evidence of HPV-16 and/or HPV-18 in Cervical Samples

    Participants with no histologic (i.e., biopsies or excisional treatment) evidence of cervical HSIL, no evidence of HPV-16 and/or HPV-18 at Week 36, and participants who did not have unscheduled excision or biopsy sample obtained between the initial dose up to Week 36 were considered to be responders. No evidence of HSIL was defined by histology as negative, squamous atypia, or low-grade intraepithelial lesion (LSIL). Cervical samples for HPV-16 and/or HPV-18 were collected using the ThinPrep™. The efficacy time frame is defined by a biopsy or surgical excision at any time starting from 14 days prior to the protocol-specified target date of Week 36. The first tissue removal sample within the time frame determines the histology endpoint.

    Time frame: At Week 36

  6. Baseline Biomarker-positive Participants for ITT Population: Percentage of Participants With No Histologic Evidence of Cervical HSIL on Histology Sample

    Baseline biomarker-positive participants with no histologic (i.e., biopsies or excisional treatment) evidence of cervical HSIL at Week 36 and participants who did not have unscheduled excision or biopsy sample obtained between the initial dose up to Week 36 were considered to be responders. No evidence of HSIL was defined by histology as negative, squamous atypia, or LSIL. The efficacy time frame is defined by a biopsy or surgical excision at any time starting from 14 days prior to the protocol-specified target date of Week 36. The first tissue removal sample within the time frame determines the histology endpoint.

    Time frame: At Week 36

  7. ITT Population: Percentage of Participants With No Histologic Evidence of Cervical HSIL on Histology Sample

    Participants with no histologic (i.e., biopsies or excisional treatment) evidence of cervical HSIL at Week 36 and participants who did not have unscheduled excision or biopsy sample obtained between the initial dose up to Week 36 were considered to be responders. No evidence of HSIL was defined by histology as negative, squamous atypia, or LSIL. The efficacy time frame is defined by a biopsy or surgical excision at any time starting from 14 days prior to the protocol-specified target date of Week 36. The first tissue removal sample within the time frame determines the histology endpoint.

    Time frame: At Week 36

  8. Baseline Biomarker-positive Participants for ITT Population: Percentage of Participants With No Evidence of HPV-16 and/or HPV-18 in Cervical Samples by Type Specific HPV Testing

    Baseline biomarker-positive participants with no evidence of HPV-16 and/or HPV-18 at Week 36 time frame and participants in whom an excision or biopsy sample was not obtained between the initial dose up to Week 36 were considered to be responders. Cervical samples for HPV-16 and/or HPV-18 were collected using the ThinPrep™. The efficacy time frame is defined by a biopsy or surgical excision at any time starting from 14 days prior to the protocol-specified target date of Week 36. The first tissue removal sample within the time frame determines the histology endpoint.

    Time frame: At Week 36

  9. ITT Population: Percentage of Participants With No Evidence of HPV-16 and/or HPV-18 in Cervical Samples by Type Specific HPV Testing

    Participants with no evidence of HPV-16 and/or HPV-18 at Week 36 and participants who did not have unscheduled excision or biopsy sample obtained between the initial dose up to Week 36 were considered to be responders. Cervical samples for HPV-16 and/or HPV-18 were collected using the ThinPrep™. The efficacy time frame is defined by a biopsy or surgical excision at any time starting from 14 days prior to the protocol-specified target date of Week 36. The first tissue removal sample within the time frame determines the histology endpoint.

    Time frame: At Week 36

  10. Baseline Biomarker-positive Participants for ITT Population: Percentage of Participants With No Histologic Evidence of LSIL or HSIL on Histology Sample

    Baseline biomarker-positive participants with no histologic evidence of cervical HSIL, squamous atypia, or LSIL at Week 36 and participants who did not have unscheduled excision or biopsy sample obtained between the initial dose up to Week 36 were considered to be responders. No evidence of LSIL was defined as no evidence of cervical squamous intraepithelial neoplasia 1 (CIN1), CIN2, or CIN3 on biopsies or excisional treatment. No evidence of HSIL was defined by histology as negative, squamous atypia, or LSIL. The efficacy time frame is defined by a biopsy or surgical excision at any time starting from 14 days prior to the protocol-specified target date of Week 36. The first tissue removal sample within the time frame determines the histology endpoint.

    Time frame: At Week 36

  11. ITT Population: Percentage of Participants With No Evidence of Histologic LSIL or HSIL on Histology Sample

    Participants with no histologic evidence of cervical HSIL, squamous atypia, or LSIL at Week 36 and participants who did not have unscheduled excision or biopsy sample obtained between the initial dose up to Week 36 were considered to be responders. No evidence of LSIL was defined as no evidence of CIN1, CIN2, or CIN3 on biopsies or excisional treatment. No evidence of HSIL was defined by histology as negative, squamous atypia, or LSIL. The efficacy time frame is defined by a biopsy or surgical excision at any time starting from 14 days prior to the protocol-specified target date of Week 36. The first tissue removal sample within the time frame determines the histology endpoint.

    Time frame: At Week 36

  12. Baseline Biomarker-positive Participants for ITT Population: Percentage of Participants With No Evidence of LSIL or HSIL on Histology Sample and No Evidence of HPV-16 and/or HPV-18 by Type Specific HPV Testing

    Baseline biomarker-positive participants with no histologic evidence of cervical HSIL, squamous atypia, or LSIL, no evidence of HPV-16 and/or HPV-18 by type specific HPV testing at Week 36, and participants who did not have unscheduled excision or biopsy sample obtained between the initial dose up to Week 36 were considered to be responders. No evidence of LSIL was defined as no evidence of CIN1, CIN2, or CIN3 on biopsies or excisional treatment. No evidence of HSIL was defined by histology as negative, squamous atypia, or LSIL. The efficacy time frame is defined by a biopsy or surgical excision at any time starting from 14 days prior to the protocol-specified target date of Week 36. The first tissue removal sample within the time frame determines the histology endpoint.

    Time frame: At Week 36

  13. ITT Population: Percentage of Participants With No Evidence of LSIL or HSIL on Histology Sample and No Evidence of HPV-16 and/or HPV-18 by Type Specific HPV Testing

    Participants with no histologic evidence of cervical HSIL, squamous atypia, or LSIL, no evidence of HPV-16 and/or HPV-18 by type specific HPV testing at Week 36, and participants who did not have unscheduled excision or biopsy sample obtained between the initial dose up to Week 36 were considered to be responders. No evidence of LSIL was defined as no evidence of CIN1, CIN2, or CIN3 on biopsies or excisional treatment. No evidence of HSIL was defined by histology as negative, squamous atypia, or LSIL. The efficacy time frame is defined by a biopsy or surgical excision at any time starting from 14 days prior to the protocol-specified target date of Week 36. The first tissue removal sample within the time frame determines the histology endpoint.

    Time frame: At Week 36

  14. Baseline Biomarker-positive Participants for ITT Population: Percentage of Participants With No Progression of Cervical HSIL to Cervical Carcinoma

    Baseline biomarker-positive participants with no histologic evidence of cervical adenocarcinoma in situ (AIS) or cervical carcinoma at Week 36 relative to baseline and participants in whom an excision or biopsy sample was not obtained between initial dose up to Week 36 were considered as responders. The efficacy time frame is defined by a biopsy or surgical excision at any time starting from 14 days prior to the protocol-specified target date of Week 36. The first tissue removal sample within the time frame determines the histology endpoint.

    Time frame: From Baseline at Week 36

  15. ITT Population: Percentage of Participants With No Progression of Cervical HSIL to Cervical Carcinoma

    Participants with no histologic evidence of cervical AIS or cervical carcinoma at Week 36 relative to baseline and participants who did not have unscheduled excision or biopsy sample obtained between the initial dose up to Week 36 were considered to be responders. The efficacy time frame is defined by a biopsy or surgical excision at any time starting from 14 days prior to the protocol-specified target date of Week 36. The first tissue removal sample within the time frame determines the histology endpoint.

    Time frame: From Baseline at Week 36

  16. Baseline Biomarker-positive Participants for ITT Population: Percentage of Participants Who Have Cleared HPV-16 and/or HPV-18 in Non-cervical Anatomic Locations

    Percentage of baseline biomarker-positive participants who have cleared HPV-16 and/or HPV-18 on specimens from non-cervical anatomic locations (oropharynx, vagina and intra-anal) at Week 36 Visit compared to baseline were reported.

    Time frame: From Baseline at Week 36

  17. ITT Population: Percentage of Participants Who Have Cleared HPV-16 and/or HPV-18 in Non-cervical Anatomic Locations

    Percentage of participants who have cleared HPV-16 and/or HPV-18 on specimens from non-cervical anatomic locations (oropharynx, vagina, and intra-anal) at Week 36 Visit compared to baseline were reported.

    Time frame: From Baseline at Week 36

  18. Baseline Biomarker-positive Participants for mITT Population: Serum Concentrations of Anti-HPV-16 and Anti-HPV-18 Antibody

    A standardized binding enzyme-linked immunosorbent assay (ELISA) was performed to measure the anti-HPV-16/18 antibody response induced by VGX-3100. E7 is a viral protein produced by cells infected by HPV-16/18.

    Time frame: At Week 15 and Week 36

  19. mITT Population: Serum Concentrations of Anti-HPV-16 and Anti-HPV-18 Antibody

    A standardized binding ELISA was performed to measure the anti-HPV-16/18 antibody response induced by VGX-3100. E7 is a viral protein produced by cells infected by HPV-16/18.

    Time frame: At Week 15 and Week 36

  20. Baseline Biomarker-positive Participants for mITT Population: Change From Baseline in Interferon-Gamma Response Magnitude at Week 15 and 36

    Assessment of cellular immune activity occurred via the application of the Interferon-γ enzyme-linked immunosorbent spot (IFN-γ ELISpot). Peripheral blood mononuclear cells (PBMCs) isolated from whole blood sample were used for analysis. E6 and E7 are viral proteins produced by cells infected by HPV-16/18.

    Time frame: Baseline; Week 15 and Week 36

  21. mITT Population: Change From Baseline in Interferon-Gamma Response Magnitude at Week 15 and 36

    Assessment of cellular immune activity occurred via the application of the IFN-γ ELISpot. PBMCs isolated from whole blood sample were used for analysis. E6 and E7 are viral proteins produced by cells infected by HPV-16/18.

    Time frame: Baseline; Week 15 and Week 36

  22. Baseline Biomarker-positive Participants for mITT Population: Change From Baseline in Flow Cytometry Response Magnitude at Week 15

    Assessment of cellular immune activity was measured using the application flow cytometry for the purposes of performing a Lytic Granule Loading Assay. The Lytic Granule Loading assay examines the following external cellular markers: CD3, CD4, CD8 (T cell identification), CD137, CD38, and CD69 (T cell activation markers) as well as PD-1 (exhaustion/activation marker). Here, changes from baseline in the percentage of CD8+CD137+Perforin+, CD8+CD38+Perforin+, and CD8+CD69+Perforin+ are reported.

    Time frame: Baseline, Week 15

  23. mITT Population: Change From Baseline in Flow Cytometry Response Magnitude at Week 15

    Assessment of cellular immune activity was measured using the application flow cytometry for the purposes of performing a Lytic Granule Loading Assay. The Lytic Granule Loading assay examines the following external cellular markers: CD3, CD4, CD8 (T cell identification), CD137, CD38, and CD69 (T cell activation markers) as well as PD-1 (exhaustion/activation marker). Here, changes from baseline in the percentage of CD8+CD137+Perforin+, CD8+CD38+Perforin+, and CD8+CD69+Perforin+ are reported.

    Time frame: Baseline, Week 15

07

Results

Posted Oct 17, 2024

Participant flow

Participants took part in the study at 53 study sites from 28 February 2019 to 15 September 2022.

Participant flow — Overall Study
MilestoneVGX-3100 + EPMatched Placebo + EP
Started13469
Intent-to-treat (itt) population13469
Baseline biomarker-positive participants for itt214
Safety set13468
Modified itt (mitt) population13068
Completed12164
Not completed135
Withdrew: Withdrawal by subject61
Withdrew: Adverse event11
Withdrew: Progressive disease10
Withdrew: Lost to follow-up51
Withdrew: Reason not specified02

Outcome measures

PrimaryBaseline Biomarker-positive Participants for ITT Population: Percentage of Participants With No Histologic Evidence of Cervical HSIL on Histology Sample and No Evidence of HPV-16 and/or HPV-18 in Cervical Samples

Baseline biomarker-positive participants with no histologic (i.e., biopsies or excisional treatment) evidence of cervical HSIL, no evidence of HPV-16 and/or HPV-18 at Week 36, and participants who did not have unscheduled excision or biopsy sample obtained between the initial dose up to Week 36 were considered to be responders. No evidence of HSIL was defined by histology as negative, squamous atypia, or low-grade intraepithelial lesion (LSIL). Cervical samples for HPV-16 and/or HPV-18 were collected using the ThinPrep™. The efficacy time frame is defined by a biopsy or surgical excision at any time starting from 14 days prior to the protocol-specified target date of Week 36. The first tissue removal sample within the time frame determines the histology endpoint.

Time frame:
At Week 36
Reported as:
Number · percentage of participants
Baseline Biomarker-positive Participants for ITT Population: Percentage of Participants With No Histologic Evidence of Cervical HSIL on Histology Sample and No Evidence of HPV-16 and/or HPV-18 in Cervical Samples
percentage of participantsVGX-3100 + EPMatched Placebo + EP
Baseline Biomarker-positive Participants for ITT Population: Percentage of Participants With No Histologic Evidence of Cervical HSIL on Histology Sample and No Evidence of HPV-16 and/or HPV-18 in Cervical Samples28.60
Statistical analysis
  • VGX-3100 + EP vs Matched Placebo + EP · Miettinen and Nurminen method · p = 0.115 · Difference in percentage: 28.6 · 95% CI -24.6 to 50.4
SecondaryBaseline Biomarker-positive Participants for Safety Population: Number of Participants With Any Local and Systemic Adverse Events (AEs)

An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of the pharmaceutical product, whether or not considered related to the pharmaceutical product. Pre-existing conditions which worsen during a study are also considered as AEs. Nausea, fatigue, injection site bruising, injection site erythema, injection site haematoma, injection site induration, injection site pain, injection site pruritus, injection site swelling, malaise, pyrexia, arthralgia, myalgia, headache and erythema were considered as local and systemic AEs for baseline biomarker-positive participants for safety population.

Time frame:
From Baseline to Week 40
Reported as:
Count of participants · Participants
Baseline Biomarker-positive Participants for Safety Population: Number of Participants With Any Local and Systemic Adverse Events (AEs)
ParticipantsVGX-3100 + EPMatched Placebo + EP
Nausea60
Fatigue102
Injection Site Bruising71
Injection Site Erythema42
Injection Site Haematoma10
Injection Site Induration10
Injection Site Pain194
Injection Site Pruritus72
Injection Site Swelling102
Malaise21
Pyrexia40
Arthralgia60
Myalgia132
Headache133
Erythema10
SecondarySafety Population: Number of Participants With Local and Systemic AEs

An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of the pharmaceutical product, whether or not considered related to the pharmaceutical product. Pre-existing conditions which worsen during a study are also considered as AEs. Nausea, chills, fatigue, injection site bruising, injection site erythema, injection site haematoma, injection site haemorrhage, injection site induration, injection site oedema, injection site pain, injection site paraesthesia, injection site pruritus, injection site swelling, malaise, pain, pyrexia, temperature regulation disorder, arthralgia, myalgia, headache and erythema were considered as local and systemic AEs for safety population.

Time frame:
From Baseline to Week 40
Reported as:
Count of participants · Participants
Safety Population: Number of Participants With Local and Systemic AEs
ParticipantsVGX-3100 + EPMatched Placebo + EPMixed Treatment
Nausea36170
Chills210
Fatigue56331
Injection Site Bruising21110
Injection Site Erythema36150
Injection Site Haematoma1070
Injection Site Haemorrhage100
Injection Site Induration300
Injection Site Oedema520
Injection Site Pain123581
Injection Site Paraesthesia100
Injection Site Pruritus33220
Injection Site Swelling43190
Malaise18121
Pain110
Pyrexia1150
Temperature Regulation Disorder100
Arthralgia29140
Myalgia56290
Headache66370
Erythema100
SecondaryBaseline Biomarker-positive Participants for Safety Population: Number of Participants With Any Treatment Emergent AEs (TEAEs) and Serious TEAEs (Including Suspected Unexpected Serious Adverse Reaction [SUSAR] and Unexpected Adverse Device Effect [UADE])

AE is any untoward medical occurrence in a participant administered a pharmaceutical product, which does not necessarily have a causal relationship with the treatment. Serious AE (SAE) is any experience that suggested significant hazard, contraindication, side effect/precaution, \& fulfilled any of the following: fatal, life-threatening, required in-patient hospitalization/prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was medically significant/required intervention to prevent other outcomes. TEAEs are any AEs starting on or after the first administration of any investigational product (IP). TEAEs included both serious and non-serious TEAEs. UADE is any SAE on health/safety or any life-threatening problem/death caused by, or associated with a device, if that effect, problem/death was not previously identified in nature, severity/degree of incidence in the investigational plan or application.

Time frame:
From Baseline to Week 40
Reported as:
Count of participants · Participants
Baseline Biomarker-positive Participants for Safety Population: Number of Participants With Any Treatment Emergent AEs (TEAEs) and Serious TEAEs (Including Suspected Unexpected Serious Adverse Reaction [SUSAR] and Unexpected Adverse Device Effect [UADE])
ParticipantsVGX-3100 + EPMatched Placebo + EP
Participants with any TEAEs204
Participants with any Serious TEAEs30
Participants with SUSAR00
Participants with UADE00
SecondarySafety Population: Number of Participants With Any TEAEs and Serious TEAEs (Including SUSAR and UADE)

AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have a causal relationship with the treatment. SAE is any experience that suggested significant hazard, contraindication, side effect, or precaution, and fulfilled any of the following criteria: fatal, life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was medically significant or required intervention to prevent other outcomes. TEAEs are defined as AEs starting on or after the first administration of any IP. TEAEs included both serious and non-serious TEAEs. UADE is any SAE on health/safety or any life-threatening problem/death caused by, or associated with a device, if that effect, problem/death was not previously identified in nature, severity/degree of incidence in the investigational plan or application.

Time frame:
From Baseline to Week 40
Reported as:
Count of participants · Participants
Safety Population: Number of Participants With Any TEAEs and Serious TEAEs (Including SUSAR and UADE)
ParticipantsVGX-3100 + EPMatched Placebo + EPMixed Treatment
Participants with any TEAEs131671
Participants with any Serious TEAEs990
Participants with SUSAR000
Participants with UADE000
SecondaryITT Population: Percentage of Participants With No Histologic Evidence of Cervical HSIL on Histology Sample and No Evidence of HPV-16 and/or HPV-18 in Cervical Samples

Participants with no histologic (i.e., biopsies or excisional treatment) evidence of cervical HSIL, no evidence of HPV-16 and/or HPV-18 at Week 36, and participants who did not have unscheduled excision or biopsy sample obtained between the initial dose up to Week 36 were considered to be responders. No evidence of HSIL was defined by histology as negative, squamous atypia, or low-grade intraepithelial lesion (LSIL). Cervical samples for HPV-16 and/or HPV-18 were collected using the ThinPrep™. The efficacy time frame is defined by a biopsy or surgical excision at any time starting from 14 days prior to the protocol-specified target date of Week 36. The first tissue removal sample within the time frame determines the histology endpoint.

Time frame:
At Week 36
Reported as:
Number · percentage of participants
ITT Population: Percentage of Participants With No Histologic Evidence of Cervical HSIL on Histology Sample and No Evidence of HPV-16 and/or HPV-18 in Cervical Samples
percentage of participantsVGX-3100 + EPMatched Placebo + EP
ITT Population: Percentage of Participants With No Histologic Evidence of Cervical HSIL on Histology Sample and No Evidence of HPV-16 and/or HPV-18 in Cervical Samples27.68.7
Statistical analysis
  • VGX-3100 + EP vs Matched Placebo + EP · Miettinen and Nurminen method · p = 0.001 · Difference in percentage: 18.9 · 95% CI 7.8 to 28.6
SecondaryBaseline Biomarker-positive Participants for ITT Population: Percentage of Participants With No Histologic Evidence of Cervical HSIL on Histology Sample

Baseline biomarker-positive participants with no histologic (i.e., biopsies or excisional treatment) evidence of cervical HSIL at Week 36 and participants who did not have unscheduled excision or biopsy sample obtained between the initial dose up to Week 36 were considered to be responders. No evidence of HSIL was defined by histology as negative, squamous atypia, or LSIL. The efficacy time frame is defined by a biopsy or surgical excision at any time starting from 14 days prior to the protocol-specified target date of Week 36. The first tissue removal sample within the time frame determines the histology endpoint.

Time frame:
At Week 36
Reported as:
Number · percentage of participants
Baseline Biomarker-positive Participants for ITT Population: Percentage of Participants With No Histologic Evidence of Cervical HSIL on Histology Sample
percentage of participantsVGX-3100 + EPMatched Placebo + EP
Baseline Biomarker-positive Participants for ITT Population: Percentage of Participants With No Histologic Evidence of Cervical HSIL on Histology Sample38.125.0
Statistical analysis
  • VGX-3100 + EP vs Matched Placebo + EP · Difference in percentage: 13.1 · 95% CI -37.7 to 46.0
SecondaryITT Population: Percentage of Participants With No Histologic Evidence of Cervical HSIL on Histology Sample

Participants with no histologic (i.e., biopsies or excisional treatment) evidence of cervical HSIL at Week 36 and participants who did not have unscheduled excision or biopsy sample obtained between the initial dose up to Week 36 were considered to be responders. No evidence of HSIL was defined by histology as negative, squamous atypia, or LSIL. The efficacy time frame is defined by a biopsy or surgical excision at any time starting from 14 days prior to the protocol-specified target date of Week 36. The first tissue removal sample within the time frame determines the histology endpoint.

Time frame:
At Week 36
Reported as:
Number · percentage of participants
ITT Population: Percentage of Participants With No Histologic Evidence of Cervical HSIL on Histology Sample
percentage of participantsVGX-3100 + EPMatched Placebo + EP
ITT Population: Percentage of Participants With No Histologic Evidence of Cervical HSIL on Histology Sample34.321.7
Statistical analysis
  • VGX-3100 + EP vs Matched Placebo + EP · Difference in percentage: 12.6 · 95% CI -0.8 to 24.5
SecondaryBaseline Biomarker-positive Participants for ITT Population: Percentage of Participants With No Evidence of HPV-16 and/or HPV-18 in Cervical Samples by Type Specific HPV Testing

Baseline biomarker-positive participants with no evidence of HPV-16 and/or HPV-18 at Week 36 time frame and participants in whom an excision or biopsy sample was not obtained between the initial dose up to Week 36 were considered to be responders. Cervical samples for HPV-16 and/or HPV-18 were collected using the ThinPrep™. The efficacy time frame is defined by a biopsy or surgical excision at any time starting from 14 days prior to the protocol-specified target date of Week 36. The first tissue removal sample within the time frame determines the histology endpoint.

Time frame:
At Week 36
Reported as:
Number · percentage of participants
Baseline Biomarker-positive Participants for ITT Population: Percentage of Participants With No Evidence of HPV-16 and/or HPV-18 in Cervical Samples by Type Specific HPV Testing
percentage of participantsVGX-3100 + EPMatched Placebo + EP
Baseline Biomarker-positive Participants for ITT Population: Percentage of Participants With No Evidence of HPV-16 and/or HPV-18 in Cervical Samples by Type Specific HPV Testing38.10
Statistical analysis
  • VGX-3100 + EP vs Matched Placebo + EP · Difference in percentage: 38.1 · 95% CI -15.7 to 59.5
SecondaryITT Population: Percentage of Participants With No Evidence of HPV-16 and/or HPV-18 in Cervical Samples by Type Specific HPV Testing

Participants with no evidence of HPV-16 and/or HPV-18 at Week 36 and participants who did not have unscheduled excision or biopsy sample obtained between the initial dose up to Week 36 were considered to be responders. Cervical samples for HPV-16 and/or HPV-18 were collected using the ThinPrep™. The efficacy time frame is defined by a biopsy or surgical excision at any time starting from 14 days prior to the protocol-specified target date of Week 36. The first tissue removal sample within the time frame determines the histology endpoint.

Time frame:
At Week 36
Reported as:
Number · percentage of participants
ITT Population: Percentage of Participants With No Evidence of HPV-16 and/or HPV-18 in Cervical Samples by Type Specific HPV Testing
percentage of participantsVGX-3100 + EPMatched Placebo + EP
ITT Population: Percentage of Participants With No Evidence of HPV-16 and/or HPV-18 in Cervical Samples by Type Specific HPV Testing38.110.1
Statistical analysis
  • VGX-3100 + EP vs Matched Placebo + EP · Difference in percentage: 27.9 · 95% CI 16.0 to 38.2
SecondaryBaseline Biomarker-positive Participants for ITT Population: Percentage of Participants With No Histologic Evidence of LSIL or HSIL on Histology Sample

Baseline biomarker-positive participants with no histologic evidence of cervical HSIL, squamous atypia, or LSIL at Week 36 and participants who did not have unscheduled excision or biopsy sample obtained between the initial dose up to Week 36 were considered to be responders. No evidence of LSIL was defined as no evidence of cervical squamous intraepithelial neoplasia 1 (CIN1), CIN2, or CIN3 on biopsies or excisional treatment. No evidence of HSIL was defined by histology as negative, squamous atypia, or LSIL. The efficacy time frame is defined by a biopsy or surgical excision at any time starting from 14 days prior to the protocol-specified target date of Week 36. The first tissue removal sample within the time frame determines the histology endpoint.

Time frame:
At Week 36
Reported as:
Number · percentage of participants
Baseline Biomarker-positive Participants for ITT Population: Percentage of Participants With No Histologic Evidence of LSIL or HSIL on Histology Sample
percentage of participantsVGX-3100 + EPMatched Placebo + EP
Baseline Biomarker-positive Participants for ITT Population: Percentage of Participants With No Histologic Evidence of LSIL or HSIL on Histology Sample38.125.0
Statistical analysis
  • VGX-3100 + EP vs Matched Placebo + EP · Difference in percentage: 13.1 · 95% CI -37.7 to 46.0
SecondaryITT Population: Percentage of Participants With No Evidence of Histologic LSIL or HSIL on Histology Sample

Participants with no histologic evidence of cervical HSIL, squamous atypia, or LSIL at Week 36 and participants who did not have unscheduled excision or biopsy sample obtained between the initial dose up to Week 36 were considered to be responders. No evidence of LSIL was defined as no evidence of CIN1, CIN2, or CIN3 on biopsies or excisional treatment. No evidence of HSIL was defined by histology as negative, squamous atypia, or LSIL. The efficacy time frame is defined by a biopsy or surgical excision at any time starting from 14 days prior to the protocol-specified target date of Week 36. The first tissue removal sample within the time frame determines the histology endpoint.

Time frame:
At Week 36
Reported as:
Number · percentage of participants
ITT Population: Percentage of Participants With No Evidence of Histologic LSIL or HSIL on Histology Sample
percentage of participantsVGX-3100 + EPMatched Placebo + EP
ITT Population: Percentage of Participants With No Evidence of Histologic LSIL or HSIL on Histology Sample32.114.5
Statistical analysis
  • VGX-3100 + EP vs Matched Placebo + EP · Difference in percentage: 17.6 · 95% CI 5.2 to 28.5
SecondaryBaseline Biomarker-positive Participants for ITT Population: Percentage of Participants With No Evidence of LSIL or HSIL on Histology Sample and No Evidence of HPV-16 and/or HPV-18 by Type Specific HPV Testing

Baseline biomarker-positive participants with no histologic evidence of cervical HSIL, squamous atypia, or LSIL, no evidence of HPV-16 and/or HPV-18 by type specific HPV testing at Week 36, and participants who did not have unscheduled excision or biopsy sample obtained between the initial dose up to Week 36 were considered to be responders. No evidence of LSIL was defined as no evidence of CIN1, CIN2, or CIN3 on biopsies or excisional treatment. No evidence of HSIL was defined by histology as negative, squamous atypia, or LSIL. The efficacy time frame is defined by a biopsy or surgical excision at any time starting from 14 days prior to the protocol-specified target date of Week 36. The first tissue removal sample within the time frame determines the histology endpoint.

Time frame:
At Week 36
Reported as:
Number · percentage of participants
Baseline Biomarker-positive Participants for ITT Population: Percentage of Participants With No Evidence of LSIL or HSIL on Histology Sample and No Evidence of HPV-16 and/or HPV-18 by Type Specific HPV Testing
percentage of participantsVGX-3100 + EPMatched Placebo + EP
Baseline Biomarker-positive Participants for ITT Population: Percentage of Participants With No Evidence of LSIL or HSIL on Histology Sample and No Evidence of HPV-16 and/or HPV-18 by Type Specific HPV Testing28.60
Statistical analysis
  • VGX-3100 + EP vs Matched Placebo + EP · Difference in percentage: 28.6 · 95% CI -24.6 to 50.4
SecondaryITT Population: Percentage of Participants With No Evidence of LSIL or HSIL on Histology Sample and No Evidence of HPV-16 and/or HPV-18 by Type Specific HPV Testing

Participants with no histologic evidence of cervical HSIL, squamous atypia, or LSIL, no evidence of HPV-16 and/or HPV-18 by type specific HPV testing at Week 36, and participants who did not have unscheduled excision or biopsy sample obtained between the initial dose up to Week 36 were considered to be responders. No evidence of LSIL was defined as no evidence of CIN1, CIN2, or CIN3 on biopsies or excisional treatment. No evidence of HSIL was defined by histology as negative, squamous atypia, or LSIL. The efficacy time frame is defined by a biopsy or surgical excision at any time starting from 14 days prior to the protocol-specified target date of Week 36. The first tissue removal sample within the time frame determines the histology endpoint.

Time frame:
At Week 36
Reported as:
Number · percentage of participants
ITT Population: Percentage of Participants With No Evidence of LSIL or HSIL on Histology Sample and No Evidence of HPV-16 and/or HPV-18 by Type Specific HPV Testing
percentage of participantsVGX-3100 + EPMatched Placebo + EP
ITT Population: Percentage of Participants With No Evidence of LSIL or HSIL on Histology Sample and No Evidence of HPV-16 and/or HPV-18 by Type Specific HPV Testing26.15.8
Statistical analysis
  • VGX-3100 + EP vs Matched Placebo + EP · Difference in percentage: 20.3 · 95% CI 10.1 to 29.5
SecondaryBaseline Biomarker-positive Participants for ITT Population: Percentage of Participants With No Progression of Cervical HSIL to Cervical Carcinoma

Baseline biomarker-positive participants with no histologic evidence of cervical adenocarcinoma in situ (AIS) or cervical carcinoma at Week 36 relative to baseline and participants in whom an excision or biopsy sample was not obtained between initial dose up to Week 36 were considered as responders. The efficacy time frame is defined by a biopsy or surgical excision at any time starting from 14 days prior to the protocol-specified target date of Week 36. The first tissue removal sample within the time frame determines the histology endpoint.

Time frame:
From Baseline at Week 36
Reported as:
Number · percentage of participants
Baseline Biomarker-positive Participants for ITT Population: Percentage of Participants With No Progression of Cervical HSIL to Cervical Carcinoma
percentage of participantsVGX-3100 + EPMatched Placebo + EP
Baseline Biomarker-positive Participants for ITT Population: Percentage of Participants With No Progression of Cervical HSIL to Cervical Carcinoma76.275.0
Statistical analysis
  • VGX-3100 + EP vs Matched Placebo + EP · Difference in percentage: 1.2 · 95% CI -31.2 to 50.5
SecondaryITT Population: Percentage of Participants With No Progression of Cervical HSIL to Cervical Carcinoma

Participants with no histologic evidence of cervical AIS or cervical carcinoma at Week 36 relative to baseline and participants who did not have unscheduled excision or biopsy sample obtained between the initial dose up to Week 36 were considered to be responders. The efficacy time frame is defined by a biopsy or surgical excision at any time starting from 14 days prior to the protocol-specified target date of Week 36. The first tissue removal sample within the time frame determines the histology endpoint.

Time frame:
From Baseline at Week 36
Reported as:
Number · percentage of participants
ITT Population: Percentage of Participants With No Progression of Cervical HSIL to Cervical Carcinoma
percentage of participantsVGX-3100 + EPMatched Placebo + EP
ITT Population: Percentage of Participants With No Progression of Cervical HSIL to Cervical Carcinoma82.176.8
Statistical analysis
  • VGX-3100 + EP vs Matched Placebo + EP · Difference in percentage: 5.3 · 95% CI -6.0 to 17.9
SecondaryBaseline Biomarker-positive Participants for ITT Population: Percentage of Participants Who Have Cleared HPV-16 and/or HPV-18 in Non-cervical Anatomic Locations

Percentage of baseline biomarker-positive participants who have cleared HPV-16 and/or HPV-18 on specimens from non-cervical anatomic locations (oropharynx, vagina and intra-anal) at Week 36 Visit compared to baseline were reported.

Time frame:
From Baseline at Week 36
Reported as:
Number · percentage of participants
Baseline Biomarker-positive Participants for ITT Population: Percentage of Participants Who Have Cleared HPV-16 and/or HPV-18 in Non-cervical Anatomic Locations
percentage of participantsVGX-3100 + EPMatched Placebo + EP
Baseline Biomarker-positive Participants for ITT Population: Percentage of Participants Who Have Cleared HPV-16 and/or HPV-18 in Non-cervical Anatomic Locations19.025.0
Statistical analysis
  • VGX-3100 + EP vs Matched Placebo + EP · Difference in percentage: -6.0 · 95% CI -54.7 to 25.8
SecondaryITT Population: Percentage of Participants Who Have Cleared HPV-16 and/or HPV-18 in Non-cervical Anatomic Locations

Percentage of participants who have cleared HPV-16 and/or HPV-18 on specimens from non-cervical anatomic locations (oropharynx, vagina, and intra-anal) at Week 36 Visit compared to baseline were reported.

Time frame:
From Baseline at Week 36
Reported as:
Number · percentage of participants
ITT Population: Percentage of Participants Who Have Cleared HPV-16 and/or HPV-18 in Non-cervical Anatomic Locations
percentage of participantsVGX-3100 + EPMatched Placebo + EP
ITT Population: Percentage of Participants Who Have Cleared HPV-16 and/or HPV-18 in Non-cervical Anatomic Locations22.410.1
Statistical analysis
  • VGX-3100 + EP vs Matched Placebo + EP · Difference in percentage: 12.2 · 95% CI 1.1 to 21.9
SecondaryBaseline Biomarker-positive Participants for mITT Population: Serum Concentrations of Anti-HPV-16 and Anti-HPV-18 Antibody

A standardized binding enzyme-linked immunosorbent assay (ELISA) was performed to measure the anti-HPV-16/18 antibody response induced by VGX-3100. E7 is a viral protein produced by cells infected by HPV-16/18.

Time frame:
At Week 15 and Week 36
Reported as:
Median · reciprocal endpoint titer
Baseline Biomarker-positive Participants for mITT Population: Serum Concentrations of Anti-HPV-16 and Anti-HPV-18 Antibody
reciprocal endpoint titerVGX-3100 + EPMatched Placebo + EP
HPV-16 E7 at Week 15450.0 (1 to 18225)1.0 (1 to 1)
HPV-16 E7 at Week 3613.0 (1 to 18225)1.0 (1 to 18225)
HPV-18 E7 at Week 154050.0 (1 to 18225)1.0 (1 to 1)
HPV-18 E7 at Week 36675.0 (1 to 18225)1.0 (1 to 18225)
Statistical analysis
  • VGX-3100 + EP vs Matched Placebo + EP · Location shift: 449.0 · 95% CI 0.0 to 18224.0
  • VGX-3100 + EP vs Matched Placebo + EP · Location shift: 0.0 · 95% CI -18224.0 to 674.0
  • VGX-3100 + EP vs Matched Placebo + EP · Location shift: 4049.0 · 95% CI 224.0 to 18224.0
  • VGX-3100 + EP vs Matched Placebo + EP · Location shift: 74.0 · 95% CI -18000.0 to 6074.0
SecondarymITT Population: Serum Concentrations of Anti-HPV-16 and Anti-HPV-18 Antibody

A standardized binding ELISA was performed to measure the anti-HPV-16/18 antibody response induced by VGX-3100. E7 is a viral protein produced by cells infected by HPV-16/18.

Time frame:
At Week 15 and Week 36
Reported as:
Median · reciprocal endpoint titer
mITT Population: Serum Concentrations of Anti-HPV-16 and Anti-HPV-18 Antibody
reciprocal endpoint titerVGX-3100 + EPMatched Placebo + EP
HPV-16 E7 at Week 15225.0 (1 to 18225)1.0 (1 to 75)
HPV-16 E7 at Week 361.0 (1 to 18225)1.0 (1 to 18225)
HPV-18 E7 at Week 152025.0 (1 to 18225)1.0 (1 to 18225)
HPV-18 E7 at Week 36675.0 (1 to 18225)1.0 (1 to 18225)
Statistical analysis
  • VGX-3100 + EP vs Matched Placebo + EP · Location shift: 224.0 · 95% CI 224.0 to 674.0
  • VGX-3100 + EP vs Matched Placebo + EP · Location shift: 0.0 · 95% CI 0.0 to 24.0
  • VGX-3100 + EP vs Matched Placebo + EP · Location shift: 2024.0 · 95% CI 2024.0 to 6074.0
  • VGX-3100 + EP vs Matched Placebo + EP · Location shift: 674.0 · 95% CI 224.0 to 674.0
SecondaryBaseline Biomarker-positive Participants for mITT Population: Change From Baseline in Interferon-Gamma Response Magnitude at Week 15 and 36

Assessment of cellular immune activity occurred via the application of the Interferon-γ enzyme-linked immunosorbent spot (IFN-γ ELISpot). Peripheral blood mononuclear cells (PBMCs) isolated from whole blood sample were used for analysis. E6 and E7 are viral proteins produced by cells infected by HPV-16/18.

Time frame:
Baseline; Week 15 and Week 36
Reported as:
Median · spot forming units (SFU)/10^6 PBMC
Baseline Biomarker-positive Participants for mITT Population: Change From Baseline in Interferon-Gamma Response Magnitude at Week 15 and 36
spot forming units (SFU)/10^6 PBMCVGX-3100 + EPMatched Placebo + EP
HPV-16 E6: Baseline1.67 (0.0 to 11.7)4.17 (0.0 to 8.3)
HPV-16 E6: Change from Baseline at Week 1525.00 (0.0 to 73.3)0.00 (0.0 to 0.0)
HPV-16 E6: Change from Baseline at Week 3615.00 (0.0 to 38.3)0.0 (0.0 to 0.0)
HPV-16 E7: Baseline0.00 (0.0 to 5.0)1.67 (0.0 to 3.3)
HPV-16 E7: Change from Baseline at Week 1516.67 (0.0 to 85.0)0.00 (0.0 to 0.0)
HPV-16 E7: Change from Baseline at Week 365.00 (0.0 to 36.7)0.00 (0.0 to 0.0)
HPV-18 E6: Baseline0.00 (0.0 to 11.7)2.50 (0.0 to 5.0)
HPV-18 E6: Change from Baseline at Week 1526.67 (0.0 to 181.7)0.00 (0.0 to 0.0)
HPV-18 E6: Change from Baseline at Week 3611.67 (0.0 to 31.7)0.00 (0.0 to 0.0)
HPV-18 E7: Baseline0.00 (0.0 to 3.3)4.17 (0.0 to 8.3)
HPV-18 E7: Change from Baseline at Week 153.33 (0.0 to 46.7)0.00 (0.0 to 0.0)
HPV-18 E7: Change from Baseline at Week 364.17 (0.0 to 20.0)0.00 (0.0 to 0.0)
Statistical analysis
  • VGX-3100 + EP vs Matched Placebo + EP · Location shift: 25.00 · 95% CI 0.00 to 73.33
  • VGX-3100 + EP vs Matched Placebo + EP · Location shift: 15.00 · 95% CI 0.00 to 38.33
  • VGX-3100 + EP vs Matched Placebo + EP · Location shift: 16.67 · 95% CI 0.00 to 85.00
  • VGX-3100 + EP vs Matched Placebo + EP · Location shift: 5.00 · 95% CI 0.00 to 36.67
  • VGX-3100 + EP vs Matched Placebo + EP · Location shift: 26.67 · 95% CI 0.00 to 181.67
  • VGX-3100 + EP vs Matched Placebo + EP · Location shift: 11.67 · 95% CI 0.00 to 31.67
  • VGX-3100 + EP vs Matched Placebo + EP · Location shift: 3.33 · 95% CI 0.00 to 46.67
  • VGX-3100 + EP vs Matched Placebo + EP · Location shift: 4.17 · 95% CI 0.00 to 20.00
SecondarymITT Population: Change From Baseline in Interferon-Gamma Response Magnitude at Week 15 and 36

Assessment of cellular immune activity occurred via the application of the IFN-γ ELISpot. PBMCs isolated from whole blood sample were used for analysis. E6 and E7 are viral proteins produced by cells infected by HPV-16/18.

Time frame:
Baseline; Week 15 and Week 36
Reported as:
Median · SFU/10^6 PBMC
mITT Population: Change From Baseline in Interferon-Gamma Response Magnitude at Week 15 and 36
SFU/10^6 PBMCVGX-3100 + EPMatched Placebo + EP
HPV-16 E6: Baseline1.67 (0.0 to 25.0)0.00 (0.0 to 15.8)
HPV-16 E6: Change from Baseline at Week 1510.00 (0.0 to 115.0)1.67 (0.0 to 16.7)
HPV-16 E6: Change from Baseline at Week 368.33 (0.0 to 110.0)0.00 (0.0 to 23.3)
HPV-16 E7: Baseline0.00 (0.0 to 11.7)0.00 (0.0 to 15.0)
HPV-16 E7: Change from Baseline at Week 156.67 (0.0 to 236.7)0.00 (0.0 to 21.7)
HPV-16 E7: Change from Baseline at Week 363.33 (0.0 to 101.7)0.00 (0.0 to 8.3)
HPV-18 E6: Baseline0.00 (0.0 to 11.7)0.00 (0.0 to 11.7)
HPV-18 E6: Change from Baseline at Week 1526.67 (0.0 to 885.0)0.00 (0.0 to 68.3)
HPV-18 E6: Change from Baseline at Week 3619.17 (0.0 to 510.0)0.00 (0.0 to 35.0)
HPV-18 E7: Baseline0.00 (0.0 to 13.3)0.00 (0.0 to 18.3)
HPV-18 E7: Change from Baseline at Week 155.83 (0.0 to 291.7)0.00 (0.0 to 15.0)
HPV-18 E7: Change from Baseline at Week 363.33 (0.0 to 246.7)0.00 (0.0 to 135.0)
Statistical analysis
  • VGX-3100 + EP vs Matched Placebo + EP · Location shift: 8.33 · 95% CI 3.33 to 11.67
  • VGX-3100 + EP vs Matched Placebo + EP · Location shift: 5.83 · 95% CI 3.33 to 11.67
  • VGX-3100 + EP vs Matched Placebo + EP · Location shift: 5.00 · 95% CI 1.67 to 11.67
  • VGX-3100 + EP vs Matched Placebo + EP · Location shift: 1.67 · 95% CI 0.00 to 5.00
  • VGX-3100 + EP vs Matched Placebo + EP · Location shift: 25.00 · 95% CI 15.00 to 40.00
  • VGX-3100 + EP vs Matched Placebo + EP · Location shift: 16.67 · 95% CI 10.00 to 28.33
  • VGX-3100 + EP vs Matched Placebo + EP · Location shift: 3.33 · 95% CI 1.67 to 6.67
  • VGX-3100 + EP vs Matched Placebo + EP · Location shift: 1.67 · 95% CI 0.00 to 3.33
SecondaryBaseline Biomarker-positive Participants for mITT Population: Change From Baseline in Flow Cytometry Response Magnitude at Week 15

Assessment of cellular immune activity was measured using the application flow cytometry for the purposes of performing a Lytic Granule Loading Assay. The Lytic Granule Loading assay examines the following external cellular markers: CD3, CD4, CD8 (T cell identification), CD137, CD38, and CD69 (T cell activation markers) as well as PD-1 (exhaustion/activation marker). Here, changes from baseline in the percentage of CD8+CD137+Perforin+, CD8+CD38+Perforin+, and CD8+CD69+Perforin+ are reported.

Time frame:
Baseline, Week 15
Reported as:
Median · percentage of cells
Baseline Biomarker-positive Participants for mITT Population: Change From Baseline in Flow Cytometry Response Magnitude at Week 15
percentage of cellsVGX-3100 + EPMatched Placebo + EP
CD8+CD137+Perforin+: Baseline0.000 (0.00 to 0.16)0.020 (0.00 to 0.04)
CD8+CD137+Perforin+: Change from Baseline at Week 150.035 (0.00 to 0.33)0.002 (0.00 to 0.002)
CD8+CD38+Perforin+: Baseline0.000 (0.00 to 0.04)0.027 (0.00 to 0.05)
CD8+CD38+Perforin+: Change from Baseline at Week 150.005 (0.00 to 0.21)0.000 (0.00 to 0.00)
CD8+CD69+Perforin+: Baseline0.008 (0.00 to 0.05)0.003 (0.00 to 0.01)
CD8+CD69+Perforin+: Change from Baseline at Week 150.042 (0.00 to 0.31)0.030 (0.00 to 0.05)
Statistical analysis
  • VGX-3100 + EP vs Matched Placebo + EP · Location shift: 0.033 · 95% CI -0.004 to 0.325
  • VGX-3100 + EP vs Matched Placebo + EP · Location shift: 0.005 · 95% CI 0.000 to 0.208
  • VGX-3100 + EP vs Matched Placebo + EP · Location shift: 0.014 · 95% CI -0.055 to 0.310
SecondarymITT Population: Change From Baseline in Flow Cytometry Response Magnitude at Week 15

Assessment of cellular immune activity was measured using the application flow cytometry for the purposes of performing a Lytic Granule Loading Assay. The Lytic Granule Loading assay examines the following external cellular markers: CD3, CD4, CD8 (T cell identification), CD137, CD38, and CD69 (T cell activation markers) as well as PD-1 (exhaustion/activation marker). Here, changes from baseline in the percentage of CD8+CD137+Perforin+, CD8+CD38+Perforin+, and CD8+CD69+Perforin+ are reported.

Time frame:
Baseline, Week 15
Reported as:
Median · percentage of cells
mITT Population: Change From Baseline in Flow Cytometry Response Magnitude at Week 15
percentage of cellsVGX-3100 + EPMatched Placebo + EP
CD8+CD137+Perforin+: Baseline0.000 (0.00 to 0.29)0.012 (0.00 to 0.24)
CD8+CD137+Perforin+: Change from Baseline at Week 150.049 (0.00 to 0.33)0.000 (0.00 to 0.10)
CD8+CD38+Perforin+: Baseline0.001 (0.00 to 0.09)0.007 (0.00 to 0.09)
CD8+CD38+Perforin+: Change from Baseline at Week 150.023 (0.00 to 0.27)0.000 (0.00 to 0.07)
CD8+CD69+Perforin+: Baseline0.003 (0.00 to 0.14)0.007 (0.00 to 0.09)
CD8+CD69+Perforin+: Change from Baseline at Week 150.037 (0.00 to 0.31)0.000 (0.00 to 0.06)
Statistical analysis
  • VGX-3100 + EP vs Matched Placebo + EP · Location shift: 0.041 · 95% CI 0.004 to 0.077
  • VGX-3100 + EP vs Matched Placebo + EP · Location shift: 0.011 · 95% CI 0.003 to 0.028
  • VGX-3100 + EP vs Matched Placebo + EP · Location shift: 0.034 · 95% CI 0.022 to 0.053

Adverse events

Collected over From Baseline to Week 40. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
VGX-3100 + EP0/134 (0%)9/134 (6.7%)131/134 (97.8%)
Matched Placebo + EP0/67 (0%)9/67 (13.4%)67/67 (100%)
Mixed Treatment0/1 (0%)0/1 (0%)1/1 (100%)
Most frequent serious events
Most frequent serious events
EventVGX-3100 + EPMatched Placebo + EPMixed Treatment
Cervix carcinoma stage 0Neoplasms benign, malignant and unspecified (incl cysts and polyps)4/1343/670/1
Squamous cell carcinoma of the cervixNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/1342/670/1
Adenocarcinoma of the cervixNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1341/670/1
Squamous cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/1341/670/1
Ovarian ruptureReproductive system and breast disorders0/1341/670/1
AppendicitisInfections and infestations0/1341/670/1
COVID-19Infections and infestations1/1340/670/1
Most frequent other events
Showing 10 of 18
Most frequent other events
EventVGX-3100 + EPMatched Placebo + EPMixed Treatment
Injection site painGeneral disorders123/13458/671/1
FatigueGeneral disorders56/13433/671/1
MalaiseGeneral disorders18/13412/671/1
HeadacheNervous system disorders66/13437/670/1
MyalgiaMusculoskeletal and connective tissue disorders56/13429/670/1
Injection site pruritusGeneral disorders33/13422/670/1
Injection site swellingGeneral disorders43/13419/670/1
Injection site erythemaGeneral disorders36/13415/670/1
NauseaGastrointestinal disorders36/13417/670/1
ArthralgiaMusculoskeletal and connective tissue disorders29/13414/670/1

Baseline characteristics

ITT population included all participants who were randomized.

Age, Continuous
Age, Continuous(years)VGX-3100 + EPMatched Placebo + EPTotal
Mean31.6 ± 6.9831.1 ± 7.9331.4 ± 7.30
Sex: Female, Male
Sex: Female, Male(Participants)VGX-3100 + EPMatched Placebo + EPTotal
Female13469203
Male000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)VGX-3100 + EPMatched Placebo + EPTotal
Hispanic or Latino251641
Not Hispanic or Latino10853161
Unknown or Not Reported101
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)VGX-3100 + EPMatched Placebo + EPTotal
Asian303
Black or African American8210
White11666182
Other202
Multiple516
08

Study locations

53 sites
  • Visions Clinical Research- Tucson
    Tucson, Arizona 85712, United States
  • Nuvance Health
    Danbury, Connecticut 06810, United States
  • Christiana Care Health System
    Newark, Delaware 19713, United States
  • Altus Research
    Lake Worth, Florida 33461, United States
  • Salom and Tangir LLC
    Miramar, Florida 33027, United States
  • Precision Clinical Research, LLC
    Sunrise, Florida 33351, United States
  • Augusta University
    Augusta, Georgia 30912, United States
  • Affinity Clinical Research Institute
    Oak Brook, Illinois 60523, United States
  • Praetorian Pharmaceutical Research, LLC
    Marrero, Louisiana 70072, United States
  • Unified Women's Clinical Research - Hagerstown
    Hagerstown, Maryland 21740, United States
  • Boston Medical Center
    Boston, Massachusetts 02118, United States
  • Saginaw Valley Medical Research Group LLC
    Saginaw, Michigan 48604, United States
  • Meridian Clinical Research Norfolk
    Norfolk, Nebraska 68701, United States
  • New Jersey Medical School
    Newark, New Jersey 07103, United States
  • Montefiore Medical Center
    Bronx, New York 10583, United States
  • Columbia University Medical Center
    New York, New York 10032, United States
  • Suffolk Obstetrics and Gynecology
    Port Jefferson, New York 11777, United States
  • Unified Women's Clinical Research - Greensboro
    Greensboro, North Carolina 27408, United States
  • Unified Women's Clinical Research - Morehead City
    Morehead City, North Carolina 28557, United States
  • Lyndhurst Clinical Research
    Winston-Salem, North Carolina 27103, United States
  • ClinOhio Research Services
    Columbus, Ohio 43213, United States
  • Obstetrics & Gynecology Associates, Inc.
    Fairfield, Ohio 45014, United States
  • Frontier Clinical Research-Smithfield
    Smithfield, Pennsylvania 15478, United States
  • Venus Gynecology, LLC
    Myrtle Beach, South Carolina 29572, United States
  • Women's Physician Group Suite 203
    Memphis, Tennessee 38119, United States
  • Storks Research
    Sugar Land, Texas 77479, United States
  • Group For Women - Tidewater Clinical Research Inc.
    Virginia Beach, Virginia 23456, United States
  • Instituto de Ginecología
    Rosario, Santa Fe S2000PBB, Argentina
  • Hospital Italiano de Buenos Aires
    Ciudad Autonoma de Buenos Aires, C1181ACH, Argentina
  • DIM Clinica Privada
    Ramos Mejía, B1704ETD, Argentina
  • Associação Obras Sociais Irmã Dulce Hospital Santo Antônio
    Salvador, Bahia 40420-000, Brazil
  • Hospital das Clinicas de Goiânia
    Goiânia, Goiás 74605-050, Brazil
  • Hospital Erasto Gaertner
    Curitiba, Paraná 80530-010, Brazil
  • Hospital Amaral Carvalho
    Jaú, São Paulo 17210-120, Brazil
  • Hospital Das Clinicas da Faculdade de Medicina de Ribeirão Preto - USP
    Ribeirao Preto, São Paulo 14048-900, Brazil
  • Pärnu Hospital
    Pärnu, Pärnumaa EE-80010, Estonia
  • East Tallinn Central Hospital Womens Clinic
    Tallinn, 10119, Estonia
  • Tartu University Hospital
    Tartu, 51014, Estonia
  • HUS Naistentaudit ja synnytykset
    Helsinki, Uusimaa FI-00290, Finland
  • Northern Savo Hospital District Muncipal Federation
    Kuopio, FI-70210, Finland
  • Vilnius District Central Outpatient Clinic
    Vilnius, LT-01117, Lithuania
  • Vilnius University Hospital Santaros Klinikos
    Vilnius, LT-08661, Lithuania
  • Niepubliczny Zakład Opieki Zdrowotnej Profimed
    Lublin, Lubelskie 20-880, Poland
  • Samodzielny Publiczny Szpital Kliniczny nr 1 w Lublinie
    Lublin, Lubelskie 20-880, Poland
  • Centrum Medyczne Angelius Provita
    Śląskie, 40-611, Poland
  • Puerto Rico Translational Research Center (PRTRC)
    Rio Piedras, 00935, Puerto Rico
  • Lynette Reynders Private Practice
    Centurion, Gauteng 0157, South Africa
  • University of Cape Town
    Cape Town, Western Cape 7925, South Africa
  • Hospital Universitario de Bellvitge
    L'Hospitalet de Llobregat, Barcelona 08907, Spain
  • Hospital General Universitario Gregorio Maranon
    Madrid, 28009, Spain
  • Hospital Universitario 12 de Octubre
    Madrid, 28041, Spain
  • Hospital Clinico Universitario de Valencia
    Valencia, 46010, Spain
  • Hospital Universitari i Politecnic La Fe de Valencia
    Valencia, 46026, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2019 to primary completion in Aug 2022, 41 months.

Results were first posted in Oct 2024, 2 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 25, 2018
First posted
Oct 26, 2018
StartActual
Feb 28, 2019
Primary completionActual
Aug 23, 2022
CompletionActual
Sep 15, 2022
Results first posted
Oct 17, 2024
Last update
Oct 17, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 17, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03721978
Responsible party
Sponsor
First posted
Oct 26, 2018
Start date
Feb 28, 2019
Primary completion
Aug 23, 2022
Completion
Sep 15, 2022
Results posted
Oct 17, 2024
Last update
Oct 17, 2024

Study contacts

Jeffrey Skolnik, MD
study director · Inovio Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: VGX-3100

Start the discussion